Provides AI-driven predictive models for cancer treatment planning and drug discovery.
Predictive Oncology Inc. is an innovative company dedicated to advancing personalized cancer therapies through the application of artificial intelligence (AI), primarily operating within the United States. Organized into four distinct segments, the company leverages its expertise across diverse domains to enhance cancer treatment methodologies. The Helomics segment specializes in clinical testing services, including tumor drug response testing and genomic profiling, alongside contract research services aimed at patient-centric drug discovery and clinical trials. Utilizing active learning technology, Helomics also supports diagnostic development and validation initiatives.
Within the zPREDICTA segment, Predictive Oncology develops organ-specific disease models that replicate human tissues in 3D, enabling accurate assessments of drug responses and the testing of anticancer agents. The Soluble segment focuses on providing High-Throughput Self-Interaction Chromatography services, facilitating the rapid screening and formulation of biologics for enhanced solubility and stability. This segment also offers protein stability analysis and proprietary technologies for detecting and removing bacterial endotoxins.
Furthermore, Predictive Oncology's Skyline segment features the STREAMWAY System, a fully automated, wall-mounted solution designed to minimize healthcare staff exposure to infectious fluids such as blood and irrigation fluid. Complementing its hardware offerings, Skyline provides research and development services, as well as specialized media that support the growth and preservation of cancer cells outside the patient's body, retaining their genetic and proteomic characteristics. Originally founded as Precision Therapeutics Inc. and rebranded in June 2019, Predictive Oncology Inc. continues to drive innovation from its headquarters in Eagan, Minnesota, shaping the future of personalized oncology treatments through cutting-edge technologies and research initiatives.